216 related articles for article (PubMed ID: 38095885)
1. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
[TBL] [Abstract][Full Text] [Related]
2. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
[TBL] [Abstract][Full Text] [Related]
3. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
4. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
[TBL] [Abstract][Full Text] [Related]
5. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
[TBL] [Abstract][Full Text] [Related]
6. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
Vaishampayan UN
Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
[TBL] [Abstract][Full Text] [Related]
7. Perioperative systemic therapy in renal cell carcinoma.
MacPhail C; Wood LA; Thana M
Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
[TBL] [Abstract][Full Text] [Related]
9. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
Carlo MI; Attalla K; Mazaheri Y; Gupta S; Yildirim O; Murray SJ; Coskey DT; Kotecha R; Lee CH; Feldman DR; Russo P; Patil S; Motzer RJ; Coleman JA; Durack JC; Chen YB; Akin O; Ari Hakimi A; Voss MH
Eur Urol; 2022 Jun; 81(6):570-573. PubMed ID: 35183395
[TBL] [Abstract][Full Text] [Related]
11. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
12. Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis.
Satkunasivam R; Guzman JC; Klaassen Z; Hall ME; Luckenbaugh AN; Lim K; Laviana AA; DeRosa AP; Beckermann KE; Rini B; Wallis CJ
Urol Oncol; 2022 Feb; 40(2):64.e17-64.e24. PubMed ID: 34690032
[TBL] [Abstract][Full Text] [Related]
13. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
14. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
Mori K; Quhal F; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Kimura T; Egawa S; Bensalah K; Karakiewicz PI; Schmidinger M; Shariat SF
Int Immunopharmacol; 2022 Jul; 108():108720. PubMed ID: 35339843
[TBL] [Abstract][Full Text] [Related]
15. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
19. Treatment Landscape of Renal Cell Carcinoma.
Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]